文献速递精神分裂症与精神病性障碍

TAAR1调节突触前多巴胺功能:来自精神分裂症临床前研究与1b期试验的证据

TAAR1 Regulates Presynaptic Dopamine Function: Evidence From Preclinical Studies and a Phase 1b Trial in Patients With Schizophrenia.
PubMed 文献 · Biol Psychiatry · 2025-10-21

该研究结合TAAR1基因敲除小鼠、脑切片和22例精神分裂症患者的1b期开放标签试验,发现TAAR1激动剂ulotaront可降低纹状体多巴胺合成能力,且降低幅度与阳性症状改善相关。

要点

  • TAAR1敲除小鼠纹状体多巴胺合成能力Ki显著高于野生型。
  • ulotaront减少脑切片诱发的多巴胺释放,并降低患者纹状体Ki。
  • 患者Ki降低与阳性症状改善相关,常见不良事件为嗜睡和头晕。

核心结论

  • TAAR1调节多巴胺合成与释放,辅助性ulotaront可降低精神分裂症患者突触前多巴胺功能并改善精神病性症状。

研究设计与样本

  • 临床前研究纳入TAAR1敲除与野生型小鼠共27只,并采用离体纹状体脑切片。
  • 1b期开放标签试验纳入22例有症状的精神分裂症患者,平均年龄32.5岁,72.7%为男性,接受14天辅助性ulotaront治疗。
  • 动物与人类均用[18F]-DOPA正电子发射断层扫描测量多巴胺合成能力Ki,脑切片用快速扫描循环伏安法评估多巴胺释放。

主要发现

  • TAAR1敲除小鼠纹状体Ki显著高于野生型对照(p < .05)。
  • ulotaront在单次(p < .0005)和重复(p < .005)刺激后均减少脑切片诱发的多巴胺释放。
  • 患者接受ulotaront后纹状体Ki显著降低(p < .01),尤其在壳核。
  • Ki降低与阳性症状改善相关(r = 0.5, p < .05),但与阴性症状或总症状变化无关。
  • 最常见不良事件为嗜睡和头晕。

关键数值与推荐

  • TAAR1敲除小鼠纹状体Ki显著高于野生型(p < .05)。
  • ulotaront减少脑切片多巴胺释放:单次刺激p < .0005,重复刺激p < .005。
  • 患者纹状体Ki显著降低(p < .01),Ki降低与阳性症状改善相关(r = 0.5, p < .05)。

临床怎么用

  • 提示TAAR1激动可能作为降低纹状体多巴胺合成、改善阳性症状的辅助治疗策略。
  • 嗜睡和头晕是ulotaront治疗中需关注的不良事件。

局限性

  • 临床部分为开放标签、样本量22例的1b期试验,未设对照组。
  • 临床前与临床结果需更大规模对照研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Schizophrenia remains a leading cause of disability globally. Elevated striatal dopamine (DA) synthesis capacity is a hallmark of its pathophysiology, but it is unknown whether this can be reduced and whether such reductions lead to symptom improvement. TAAR1 may regulate dopaminergic function, and ulotaront (SEP-363856), a TAAR1 agonist, offers a potential novel treatment strategy. METHODS: We conducted combined translational preclinical and clinical tests of mechanism studies. Preclinical work involved TAAR1 knockout (KO) and wild-type (WT) mice (N = 27), as well as ex vivo striatal brain slices. In a phase 1 open-label trial, 22 patients with symptomatic schizophrenia (mean age = 32.5 years; 72.7% male) received 14 days of adjunctive ulotaront treatment. DA synthesis capacity (Ki) was measured using [18F]-DOPA positron emission tomography in animals and humans. DA release in brain slices was assessed using fast-scan cyclic voltammetry. RESULTS: TAAR1-KO mice showed significantly higher striatal Ki than WT controls (p < .05). Ulotaront reduced evoked DA release in brain slices after single (p < .0005) and repeated (p < .005) stimulation. In patients, ulotaront significantly reduced striatal Ki (p < .01), particularly in the putamen. Reductions in Ki correlated with improvements in positive symptoms (r = 0.5, p < .05) but not with changes in negative or total symptoms. The most common adverse events were somnolence and dizziness. CONCLUSIONS: TAAR1 regulates DA synthesis and release. Adjunctive ulotaront reduces presynaptic DA function and psychotic symptoms in schizophrenia. These findings support TAAR1 as a promising target for treating antipsychotic nonresponsive schizophrenia and other dopaminergic disorders.

来源:Biol Psychiatry,查看原文。版权归原作者所有。

引用

  1. Howes OD, Vano LJ, Petty AE, et al. TAAR1 Regulates Presynaptic Dopamine Function: Evidence From Preclinical Studies and a Phase 1b Trial in Patients With Schizophrenia. Biol Psychiatry. 2025. PMID: 41130556. doi:10.1016/j.biopsych.2025.10.013

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。